Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. more
Time Frame | VRTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.44% | -2.06% | -0.55% |
1-Month Return | -4.18% | -1.92% | 2.72% |
3-Month Return | -5.62% | -10.4% | 7.66% |
6-Month Return | -4.23% | -4.6% | 10.15% |
1-Year Return | 10.59% | 4.06% | 27.53% |
3-Year Return | 107.74% | 1.94% | 32.31% |
5-Year Return | 104.01% | 36.48% | 89.2% |
10-Year Return | 280.07% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.16B | 6.21B | 7.57B | 8.93B | 9.87B | [{"date":"2019-12-31","value":42.18,"profit":true},{"date":"2020-12-31","value":62.88,"profit":true},{"date":"2021-12-31","value":76.75,"profit":true},{"date":"2022-12-31","value":90.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 547.76M | 736.30M | 904.20M | 1.08B | 1.26B | [{"date":"2019-12-31","value":43.4,"profit":true},{"date":"2020-12-31","value":58.33,"profit":true},{"date":"2021-12-31","value":71.64,"profit":true},{"date":"2022-12-31","value":85.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 3.62B | 5.47B | 6.67B | 7.85B | 8.61B | [{"date":"2019-12-31","value":42,"profit":true},{"date":"2020-12-31","value":63.55,"profit":true},{"date":"2021-12-31","value":77.5,"profit":true},{"date":"2022-12-31","value":91.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 86.84% | 88.14% | 88.06% | 87.90% | 87.21% | [{"date":"2019-12-31","value":98.53,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.92,"profit":true},{"date":"2022-12-31","value":99.74,"profit":true},{"date":"2023-12-31","value":98.95,"profit":true}] |
Operating Expenses | 2.41B | 2.60B | 3.89B | 3.48B | 4.78B | [{"date":"2019-12-31","value":50.53,"profit":true},{"date":"2020-12-31","value":54.45,"profit":true},{"date":"2021-12-31","value":81.49,"profit":true},{"date":"2022-12-31","value":72.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 1.20B | 2.86B | 2.78B | 4.31B | 4.31B | [{"date":"2019-12-31","value":27.8,"profit":true},{"date":"2020-12-31","value":66.31,"profit":true},{"date":"2021-12-31","value":64.59,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 202.53M | 26.89M | (108.30M) | 14.80M | 642.90M | [{"date":"2019-12-31","value":31.5,"profit":true},{"date":"2020-12-31","value":4.18,"profit":true},{"date":"2021-12-31","value":-16.85,"profit":false},{"date":"2022-12-31","value":2.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 1.39B | 3.12B | 2.73B | 4.23B | 4.38B | [{"date":"2019-12-31","value":31.85,"profit":true},{"date":"2020-12-31","value":71.16,"profit":true},{"date":"2021-12-31","value":62.34,"profit":true},{"date":"2022-12-31","value":96.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 218.11M | 405.15M | 388.30M | 910.40M | 760.20M | [{"date":"2019-12-31","value":23.96,"profit":true},{"date":"2020-12-31","value":44.5,"profit":true},{"date":"2021-12-31","value":42.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.5,"profit":true}] |
Income After Taxes | 1.18B | 2.71B | 2.34B | 3.32B | 3.62B | [{"date":"2019-12-31","value":32.51,"profit":true},{"date":"2020-12-31","value":74.92,"profit":true},{"date":"2021-12-31","value":64.71,"profit":true},{"date":"2022-12-31","value":91.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | 1.18B | 2.71B | 2.34B | 3.32B | 3.62B | [{"date":"2019-12-31","value":32.51,"profit":true},{"date":"2020-12-31","value":74.92,"profit":true},{"date":"2021-12-31","value":64.71,"profit":true},{"date":"2022-12-31","value":91.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 1.18B | 2.71B | 2.34B | 3.32B | 3.62B | [{"date":"2019-12-31","value":32.51,"profit":true},{"date":"2020-12-31","value":74.92,"profit":true},{"date":"2021-12-31","value":64.71,"profit":true},{"date":"2022-12-31","value":91.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | 5.33 | 10.32 | 13.02 | 14.89 | 15.22 | [{"date":"2019-12-31","value":35.02,"profit":true},{"date":"2020-12-31","value":67.81,"profit":true},{"date":"2021-12-31","value":85.55,"profit":true},{"date":"2022-12-31","value":97.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
VRTX | |
---|---|
Cash Ratio | 1.64 |
Current Ratio | 2.47 |
Quick Ratio | 2.20 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VRTX | |
---|---|
ROA (LTM) | 12.05% |
ROE (LTM) | -2.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VRTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.30 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.70 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VRTX | |
---|---|
Trailing PE | NM |
Forward PE | 25.45 |
P/S (TTM) | 11.34 |
P/B | 7.71 |
Price/FCF | 96 |
EV/R | 10.89 |
EV/Ebitda | 223.54 |
PEG | 1.23 |
Vertex Pharmaceuticals Inc (VRTX) share price today is $446.5
Yes, Indians can buy shares of Vertex Pharmaceuticals Inc (VRTX) on Vested. To buy Vertex Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vertex Pharmaceuticals Inc (VRTX) via the Vested app. You can start investing in Vertex Pharmaceuticals Inc (VRTX) with a minimum investment of $1.
You can invest in shares of Vertex Pharmaceuticals Inc (VRTX) via Vested in three simple steps:
The 52-week high price of Vertex Pharmaceuticals Inc (VRTX) is $519.88. The 52-week low price of Vertex Pharmaceuticals Inc (VRTX) is $391.01.
The price-to-earnings (P/E) ratio of Vertex Pharmaceuticals Inc (VRTX) is
The price-to-book (P/B) ratio of Vertex Pharmaceuticals Inc (VRTX) is 7.71
The dividend yield of Vertex Pharmaceuticals Inc (VRTX) is 0.00%
The market capitalization of Vertex Pharmaceuticals Inc (VRTX) is $120.55B
The stock symbol (or ticker) of Vertex Pharmaceuticals Inc is VRTX